THRV-1268
Thryv Licenses New SGK1 Chemistry for Brain Disease
Thryv Therapeutics Inc., a private, Montreal-based clinical-stage biopharmaceutical company, announced on September 3 that it has entered an exclusive, worldwide, royalty-bearing license agreement with three Spanish research institutions, the Spanish National Research Council (CSIC), the Autonomous University of Madrid (UAM), and the Fundación de la Universidad Autónoma de Madrid, covering a new class of SGK1…
